Linda MasatVice President of Business Development at Trianni, Inc.
Dr. Masat has 18 years of experience in discovering and developing therapeutic antibodies within global biotechnology and biopharmaceutical companies. Most recently, Linda was Director, Strategic Academic Alliances at Takeda Pharmaceutical, where she established and led collaborations with academic laboratories and early-stage companies. Prior to this role, Dr. Masat led multidisciplinary teams at Takeda, XOMA and Abgenix (now Amgen) in the discovery of therapeutic-grade biologics to over 70 targets. She is the inventor of XOMA’s gevokizumab, an IL1b antibody that was licensed to Novartis in 2017; three additional programs led by Linda entered clinical development stage and more are at IND-enabling activities. Dr. Masat received her Ph.D. in Biochemistry from the University of Urbino, Italy and did her postdoctoral training at the University of California, San Francisco.